Aleksandra Wądołowska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aleksandra Wądołowska has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Barbara Przybył
University Clinical Hospital No. 2 of the Medical University of Lodz, ul. Stefana Żeromskiego 113, 90-549 Łódź, Poland
3 shared publications - Daniel Narożniak
St. Raphael’s Voivodeship Specialist Hospital in Czerwona Góra, Czerwona Góra 10, 26-060 Chęciny, Poland
3 shared publications - Jan Wojdal
Copernicus Memorial Hospital, Pabianicka 62, 93-513 Łódź, Poland
3 shared publications - Katarzyna Ciepłucha
Rydygier Specialist Hospital in Kraków, Osiedle Złotej Jesieni 1, 31-820 Kraków, Poland
3 shared publications - Blanka Serafin-Juszczak
University Clinical Hospital No. 2 of the Medical University of Lodz, ul. Stefana Żeromskiego 113, 90-549 Łódź, Poland
2 shared publications - Karolina Kusek
Central Clinical Hospital, ul. Pomorska 251, Łódź, Poland
2 shared publications
Latest Publications
- Open Access
- 30 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(47))
SLEEP QUALITY (PSQI) AND SUMMATIVE EXAM PERFORMANCE IN MEDICAL STUDENTS
Purpose of the research: This study aimed to review the relationship between sleep quality, as measured by the Pittsburgh Sleep Quality Index (PSQI), and academic performance among medical students, highlighting neurocognitive consequences and effective interventions. Materials and methods: The review of research literature was conducted through databases such as PubMed, Google Scholar, and Scopus, including studies from 2007 to 2025. Results: Multiple studies show that poor sleep quality (PSQI >5) is highly prevalent among medical students and often correlates with reduced GPA, impaired memory, and diminished executive function. Acute sleep deprivation before exams significantly worsens performance. However, inconsistent methodologies, self-reported data, and cross-sectional designs limit causal interpretation. Despite this, evidence supports implementing sleep hygiene education, CBT-I, mindfulness training, and institutional changes to promote better sleep and academic outcomes. Conclusions: A multifaceted approach is needed to improve medical students’ sleep. Combining behavioural interventions and structural academic reforms may reduce stress, enhance cognitive performance, and support long-term academic success. Further longitudinal research using objective measures is recommended to strengthen these findings.
- 30 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(47))
Open AccessSLEEP QUALITY (PSQI) AND SUMMATIVE EXAM PERFORMANCE IN MEDICAL STUDENTS
Purpose of the research: This study aimed to review the relationship between sleep quality, as measured by the Pittsburgh Sleep Quality Index (PSQI), and academic performance among medical students, highlighting neurocognitive consequences and effective interventions. Materials and methods: The review of research literature was conducted through databases such as PubMed, Google Scholar, and Scopus, including studies from 2007 to 2025. Results: Multiple studies show that poor sleep quality (PSQI >5) is highly prevalent among medical students and often correlates with reduced GPA, impaired memory, and diminished executive function. Acute sleep deprivation before exams significantly worsens performance. However, inconsistent methodologies, self-reported data, and cross-sectional designs limit causal interpretation. Despite this, evidence supports implementing sleep hygiene education, CBT-I, mindfulness training, and institutional changes to promote better sleep and academic outcomes. Conclusions: A multifaceted approach is needed to improve medical students’ sleep. Combining behavioural interventions and structural academic reforms may reduce stress, enhance cognitive performance, and support long-term academic success. Further longitudinal research using objective measures is recommended to strengthen these findings.
- Open Access
- 30 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(47))
MENOPAUSAL HORMONE THERAPHY – APPLICATION, RISKS AND BENEFITS IN CLINICAL PRACTICE
Aim of the study: The aim of this review is to explore current evidence regarding physiological rationale, indications, contraindications and systemic use of MHT in clinical practice. Materials and methods: Literature reviewed was conducted in medical databases such as PubMed, UpToDate and relevant subject literature published within last 30 years. Results: Evidence indicates that early initiation (< 10 years after the onset of menopause) of combined estrogen-progestogen therapy significantly diminishes coronary events and prevents rapid bone loss, whereas later commencement increases ischaemic stroke and venous thrombo-embolism risk. Unopposed systemic oestrogen elevates endometrial-carcinoma incidence, and long-term systemic regimens may moderately increase breast-cancer risk. On the contrary, topical vaginal oestrogens reverse urogenital atrophy and lower recurrent urinary-tract infection rates with minimal systemic exposure. Conclusion: MHT consistently alleviates vasomotor symptoms and improves quality of life, but does not constitute first-line therapy for established osteoporosis or primary cardiovascular prevention The therapeutic value of MHT is contingent upon timing, formulation, route and patient-specific comorbidities. When used for the shortest necessary duration and accompanied by careful surveillance, MHT offers substantial symptomatic benefit with acceptable safety in appropriately selected women.
- 30 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(47))
Open AccessMENOPAUSAL HORMONE THERAPHY – APPLICATION, RISKS AND BENEFITS IN CLINICAL PRACTICE
Aim of the study: The aim of this review is to explore current evidence regarding physiological rationale, indications, contraindications and systemic use of MHT in clinical practice. Materials and methods: Literature reviewed was conducted in medical databases such as PubMed, UpToDate and relevant subject literature published within last 30 years. Results: Evidence indicates that early initiation (< 10 years after the onset of menopause) of combined estrogen-progestogen therapy significantly diminishes coronary events and prevents rapid bone loss, whereas later commencement increases ischaemic stroke and venous thrombo-embolism risk. Unopposed systemic oestrogen elevates endometrial-carcinoma incidence, and long-term systemic regimens may moderately increase breast-cancer risk. On the contrary, topical vaginal oestrogens reverse urogenital atrophy and lower recurrent urinary-tract infection rates with minimal systemic exposure. Conclusion: MHT consistently alleviates vasomotor symptoms and improves quality of life, but does not constitute first-line therapy for established osteoporosis or primary cardiovascular prevention The therapeutic value of MHT is contingent upon timing, formulation, route and patient-specific comorbidities. When used for the shortest necessary duration and accompanied by careful surveillance, MHT offers substantial symptomatic benefit with acceptable safety in appropriately selected women.
- Open Access
- 30 June 2025
- Published by Medical Education in OncoReview
- Vol. 15 (1(57)) , 3-11
Cardiotoxicity in cancer immunotherapy: from pathogenesis to prevention ? narrative review
Cancer immunotherapies, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy, improve survival but carry a risk of severe cardiotoxicity. Myocarditis is the most dangerous complication with high mortality, and its mechanism involves T-cell auto-aggression or cytokine storms. Risk management requires vigilance, monitoring of cardiac biomarkers, and imaging studies. Prompt treatment with high-dose glucocorticosteroids is crucial. Collaboration within cardio-oncology teams is fundamental for safety, and further research must focus on precise risk stratification to protect patients while maintaining therapeutic efficacy.
- 30 June 2025
- Published by Medical Education in OncoReview
- Vol. 15 (1(57)) , 3-11
Open AccessCardiotoxicity in cancer immunotherapy: from pathogenesis to prevention ? narrative review
Cancer immunotherapies, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy, improve survival but carry a risk of severe cardiotoxicity. Myocarditis is the most dangerous complication with high mortality, and its mechanism involves T-cell auto-aggression or cytokine storms. Risk management requires vigilance, monitoring of cardiac biomarkers, and imaging studies. Prompt treatment with high-dose glucocorticosteroids is crucial. Collaboration within cardio-oncology teams is fundamental for safety, and further research must focus on precise risk stratification to protect patients while maintaining therapeutic efficacy.